BridgeBio chief sells $5.9mn in shares under pre-arranged plan

Neil Kumar, chief executive of BridgeBio Pharma, has sold nearly $6mn worth of shares in the company, according to a regulatory filing.

The transactions, carried out on April 9 and 10, totalled approximately $5.97mn and were executed at prices ranging from about $73 to $76 a share. The sales were conducted through family trusts and formed part of a pre-arranged Rule 10b5-1 trading plan adopted in March 2025.

Despite the disposals, Kumar retains a substantial holding in the group, including both direct and indirect share ownership.

The sales come amid a period of strong share price performance for BridgeBio, with the stock rising sharply over the past year. The company, which focuses on genetic disease therapies, has drawn investor attention following progress across its pipeline and growing expectations for key treatments.

Analysts have recently taken a constructive view on the group’s prospects. Barclays and RBC Capital Markets have both highlighted the commercial potential of its therapies, while other brokers have pointed to blockbuster sales potential for late-stage programmes.

BridgeBio is also advancing regulatory submissions, including an application to the US Food and Drug Administration for its oral candidate BBP-418, as it seeks to build momentum across its portfolio.